Skip to content

CHOOSE FDA-APPROVED OMIDRIA FOR PROVEN SAFETY

OMIDRIA demonstrated ocular adverse reaction rates similar to placebo1

Ocular adverse reactions reported by ≥2% of subjects*

Ocular Events OMIDRIA
(n=459)
Placebo
(n=462)
Anterior chamber inflammation 111 (24%) 102 (22%)
Increased intraocular pressure 20 (4%) 15 (3%)
Posterior capsule opacification 18 (4%) 16 (4%)
Eye irritation 9 (2%) 6 (1%)
Foreign body sensation in eye 8 (2%) 11 (2%)

*Combined clinical trial results from 3 randomized, placebo-controlled studies. These adverse event rates may not reflect the rates observed in practice.

OMIDRIA demonstrated ocular adverse reaction rates similar to placebo as reported in the combined clinical trial results from 3 randomized, placebo-controlled studies.1

REFERENCE: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017.

BACK TO TOP